Computational approaches to the prediction of blood-brain barrier permeability: A comparative analysis of central nervous system drugs versus secretase inhibitors for Alzheimer's disease

Current Opinion in Drug Discovery and Development

Volumn 9, Issue 3, 2006, Pages 303-313

  Rishton, Gilbert M ^a   LaBonte, Kristen ^a   Williams, Antony J ^b   Kassam, Karim ^b   Kolovanov, Eduard ^b  

^a CALIFORNIA STATE UNIVERSITY CHANNEL ISLANDS   (United States)

^b Advanced Chemistry Development   (Canada)

Author keywords

Acetylcholine esterase inhibitors; Alzheimer's disease; Blood brain barrier; Blood brain barrier permeability; Calculated blood brain barrier permeability; CNS drugs; Drug like; Drug likeness; Lead like; Lead likeness; logBB; Secretase inhibitors

Indexed keywords

ALPRAZOLAM; BETA SECRETASE INHIBITOR; CENTRAL NERVOUS SYSTEM AGENTS; CHOLINESTERASE INHIBITOR; CITALOPRAM; DIAZEPAM; DONEPEZIL; ENZYME INHIBITOR; FLUOXETINE; GALANTAMINE; GAMMA SECRETASE INHIBITOR; MEMANTINE; PAROXETINE; RIVASTIGMINE; SERTRALINE; TACRINE; ZOLPIDEM; ZOLPIDEM TARTRATE;

ALGORITHM; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; DRUG DESIGN; DRUG PENETRATION; DRUG SCREENING; HUMAN; HYDROGEN BOND; IN VITRO STUDY; MATHEMATICAL COMPUTING; MOLECULAR WEIGHT; NONHUMAN; PHYSICAL CHEMISTRY; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ENDOPEPTIDASES; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; CENTRAL NERVOUS SYSTEM AGENTS; COMPUTER SIMULATION; ENDOPEPTIDASES; HUMANS; PROTEASE INHIBITORS;

EID: 33646849102     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Clark DE: Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena: 2. Prediction of blood-brain barrier penetration. J Pharm Sci (1999) 88(8):815-821. Describes the early development of rapid computational methods applicable to large numbers of compounds.
2. Kansy M, van de Waterbeemd H: Hydrogen-bonding capacity and brain penetration. Chimia (1992) 46:299-303.
3. Abraham MH, Chadha HS, Mitchell RC: Hydrogen bonding. 33. Factors that Influence the distribution of solutes between blood and brain. J Pharm Sci (1994) 83(9):1257-1268.
4. Abraham MH, Chadha HS, Mitchell RC: Hydrogen bonding. Part 36. Determination of blood brain distribution using octanol-water partition coefficients. Drug Des Discov (1995) 13(2):123-131.
5. Abraham MH, Takacs-Novak K, Mitchell RC: On the partition of ampholytes: Application to blood-brain distribution. J Pharm Sci (1997) 86(3):310-315.
6. Lombardo F, Blake JF, Curatolo WJ: Computation of brain-blood partitioning of organic solutes via free energy calculations. J Med Chem (1996) 39(24):4750-4755.
7. Norinder U, Sjoberg P, Osterberg T: Theoretical calculation and prediction of blood-brain partitioning of organic solutes using MolSurf parametrization and PLS statistics. J Pharm Sci (1998) 87(8):952-959.
8. Clark DE: Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J Pharm Sci (1999) 88(8):807-814.
9. Moriguchi I, Hirono S, Liu Q, Nakagome I, Matsushita Y: Simple method of calculating octanol/water partition coefficient. Chem Pharm Bull Tokyo (1992) 40(1):127-130.
10. Gumbleton M, Audus KL: Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. J Pharm Sci (2001) 90(11):1681-1698.
11. Lohmann C, Huwel S, Galla, H-J: Predicting blood-brain barrier permeability of drugs: Evaluation of different in vitro assays. J Drug Targeting (2002) 10(4):263-276.
12. Wang Q, Rager JD, Weinstein K, Kardos PS, Dobson GL, Li J, Hidalgo IJ: Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm (2005) 288(2):349-359.
13. Kansy M, Senner F, Gubernator K: Physiochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem (1998) 41(7):1007-1010.
14. Suomalainen P, Johans C, Soderlund T, Kinnunen PK: Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability. J Med Chem (2004) 47(7):1783-1788.
15. Osterberg T, Norinder U: Prediction of drug transport processes using simple parameters and PLS statistics: The use of ACD/logP and ACD/ChemSketch descriptors. Eur J Pharm Sci (2001) 12(3):327-337. Describes early research employing ACD/Labs tools to predict membrane permeability.
16. Subramanian G, Kitchen DB: Computational models to predict blood-brain barrier permeation and CNS activity. J Comput Aided Mol Des (2003) 17(10):643-664.
17. Liu X, Tu M, Kelly RS, Chen C, Smith BJ: Development of a computational approach to predict blood-brain barrier permeability. Drug Metab Dispos (2004) 32(1):132-139.
18. Ma X-L, Chen C, Yang J: Predictive model of blood-brain barrier penetration of organic compounds. Acta Pharmacol Sin (2005) 26(4):500-512.
19. Narayanan R, Gunturi SB: In silico ADME modeling: Prediction models for blood-brain barrier permeation using a systematic variable selection method. Bioorg Med Chem (2005) 13(8):3017-3028.
20. Kassam K: Estimating blood-brain barrier penetration: An example of the use of scripting in ACD/PhysChem software. Advanced Chemistry Development Inc, Toronto, ON, Canada (2006). http://www.acdlabs.com/download/technotes/90/ physchem/blood_brain.pdf
21. Physico-chemical laboratory: Advanced Chemistry Development Inc, Toronto, ON, Canada (2006). http://www.acdlabs.com/products/phys_chem_lab/
22. Pan D, Iyer M, Liu J, Li Y, Hopfinger AJ: Constructing optimum blood brain barrier QSAR models using a combination of 4D-molecular similarity measures and cluster analysis. J Chem Inf Comput Sci (2004) 44(6):2083-2098.
23. Rose K, Hall LH, Kier LB: Modeling blood-brain barrier partitioning using the electrotopological state. J Chem Inf Comput Sci (2002) 42(3):651-666.
24. 2 receptor histamine antagonists. J Med Chem (1988) 31(3):656-671.
25. Hou TJ, Xu XJ: ADME evaluation in drug discovery. 3. Modeling blood-brain barrier partitioning using simple molecular descriptors. J Chem Inf Comput Sci (2003) 43(6):2137-2152.
26. Young RC, Ganellin CR, Mitchell R, Griffiths RC, Parsons ME, Saunders D, Sore NE: An approach to the design of brain-penetrating histaminergic agonists. Eur J Med Chem (1993) 28:201-211.
27. Salminen T, Pulli A, Taskinen J: Relationship between immobilised artificial membrane chromatographic retention and the brain penetration of structurally diverse drugs. J Pharm Biomed Anal (1997) 15(4):469-477.
28. Van Belle K, Sarre S, Ebinger G, Michotte Y: Brain, liver and blood distribution kinetics of carbamazepine and its metabolic interaction with clomipramine in rats: A quantitative microdialysis study. J Pharmacol Exp Ther (1995) 272(3):1217-1222.
29. Zhang H: A new approach for the tissue-blood partition coefficients of neutral and ionized compounds. J Chem Inf Model (2005) 45(1):121-127.
30. Balaz S, Lukacova V: A model-based dependence of the human tissue/blood partition coefficients of chemicals on lipophilicity and tissue composition. Quant Struct Act Relatsh (1999) 18(4):361-368.
31. Yokogawa K, Nakashima E, Ishizaki J, Maeda H, Nagano T, Ichimura F: Relationships in the structure-tissue distribution of basic drugs in the rabbit. Pharm Res (1990) 7(7):691-696.
32. Lin JH, Chen IW, Lin TH: Blood-brain barrier permeability and in vivo activity of partial agonists of benzodiazepine receptor: A study of L-663,581 and its metabolites in rats. J Pharmacol Exp Ther (1994) 271(3):1197-1202.
33. Abraham MH, Chadha HS, Mitchell RC: Hydrogen bonding. 33. Factors that influence the distribution of solutes between blood and brain. J Pharm Sci (1994) 83(9):1257-1268.
34. Bordi F, Mor M, Plazzi PV, Silva C, Caretta A, Morini G: HPLC detection of thioperamide from biological samples and its determination in rat blood and brain after systemic administration. Farmaco (1992) 47(7-8):1095-1103.
35. Narayanan R, Gunturi SB: In silico ADME modelling: Prediction models for blood-brain barrier permeation using a systematic variable selection method. Bioorg Med Chem (2005) 13(8):3017-3028.
36. Garberg P, Ball M, Borg N, Cecchelli R, Fenart L, Hurst RD, Lindmark T, Mabondzo A, Nilsson JE, Raub TJ, Stanimirovic D et al: In vitro models for the blood-brain barrier. Toxicol Vitro (2005) 19(3):299-334.
37. Greig NH, Brossi A, Pei XF, Ingram DK, Soncrant T: Designing drugs for optimal nervous system activity. In: New Concepts of a Blood-Brain Barrier. Greenwood J, Segal BM, Begley DJ (Eds), Plenum Press, New York, NY, USA (1995):251-264.
38. Ohshima N, Kotaki H, Sawada Y, Iga T: The relationship between the pharmacological effect of amitriptyline based on an improved forced-swimming test and plasma concentration in rats. Biol Pharm Bull (1995) 18(1):70-74.
39. 1 agonist and a series of analogous tetrahydropyridines measured by in vivo microdialysis. Pharm Res (2000) 17(1):70-76.
40. Luco JM: Prediction of the brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least-squares (PLS) modeling. J Chem Inf Comput Sci (1999) 39(2):396-404.
41. Sippl W: Computational approaches for the prediction of blood-brain barrier permeation. Curr Med Chem - Cent Nerv Syst Agents (2002) 2(3):211-227. A complete review of the various approaches for BBB prediction. Specifically of interest is a comparison of the statistical results of the various prediction methods comprising a total of 22 approaches.
42. Kelder J, Groothenius PD, Bayada DM, Delbressine LP, Ploemen JP: Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res (1999) 16(10):1514-1519.
43. 1 receptors, using in vivo and in vitro techniques. J Pharmacol Exp Ther (1998) 285(3):1023-1030.
44. Rubenstein SM, Baichwal V, Beckmann H, Clark D, Frankmoelle W, Roche D, Santha E, Schwender S, Thoolen M, Ye Q, Jaen JC: Hydrophilic, prodrug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J Med Chem (2001) 44(22):3599-3605.
45. Riviere GJ, Gentry WB, Owens SM: Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. J Pharmacol Exp Ther (2000) 292(3):1042-1047.
46. Proksch JW, Gentry WB, Owens SM: The effect of rate of drug administration on the extent and time course of phencyclidine distribution in rat brain, testis, and serum. Drug Metab Dispos (2000) 28(7):742-747.
47. ACD/Dictionary: Advanced Chemistry Development Inc, Toronto, ON, Canada (2005). http://www.acdlabs.com/products/chem_dsn_lab/chem sketch/dictionary/
48. ACD/LogP DB: Advanced Chemistry Development Inc, Toronto, ON, Canada (2005). http://www.acdlabs.com/products/phys_chem_lab/logp/The algorithms used for the ACD/LogP database can be found at http://www.acdlabs.com/products/ phys_chem_lab/logp/tech.html#algo
49. ACD/LogD: Advanced Chemistry Development Inc, Toronto, ON, Canada (2005). http://www.acdlabs.com/products/phys_chem_lab/logd/
50. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD: Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem (2002) 45(12):2615-2623. Provides an important expansion of the 'rule-of-five' parameters, to include free rotational bonds as a parameter that is detrimental to intestinal absorption.
51. Norinder U, Haeberlein M: Computational approaches to the prediction of blood-brain distribution. Adv Drug Deliv Rev (2002) 54(3):291-313. Provides an excellent review of several computational protocols for modeling drug transport across the BBB, including quantum-mechanics-based approaches, molecular-mechanics-related techniques and two-dimensional-graph procedures.
52. Lipinski CA, Lombardo F, Dominy B, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (1997) 46(1-3):3-26. Describes seminal 'rule-of-thumb' descriptors for the prediction of membrane permeability and potential for oral bioavailability.
53. Martinez A, Castro A: Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease. Expert Opin Invest Drugs (2006) 15(1):1-12.
54. Nordberg A, Svensson A: Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology. Drug Saf (1999) 19(6):465-480.
55. Glenner GG, Wang CW: Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun (1984) 120(3):885-890.
56. Vassar R, Bennet BD, Babu-Kahn S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y et al: γ-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (1999) 286(5440):735-741.
57. Citron M, Diehl T, Gordon G, Biere AL, Seubert P, Selkoe DJ: Evidence that the 42- and 40-amino acid forms of amyloid β protein are generated from the β-amyloid precursor protein by different protease activities. Proc Natl Acad Sci USA (1996) 93(23):13170-13175.
58. Rishton GM: Nonleadlikeness and leadlikeness in biochemical screening. Drug Disc Today (2003) 8(2):86-96.
59. Rishton GM: Reactive compounds and in vitro false positives in HTS. Drug Disc Today (1997) 2(9)382-384.
60. Oprea TI, Bologna CG, Cristian G, Edwards BS, Prossnitz ER, Sklar LA: Post-high-throughput screening analysis: An empirical compound prioritization scheme. J Biomol Screen (2005) 10(5):419-426.
61. Teall M, Oakly P, Harrison T, Shaw D, Kay E, Elliott J, Gerhard U, Castro JL, Shearman M, Ball RG, Tsou NN: Aryl sulfones: A new class of γ-secretase inhibitors. Bioorg Med Chem Lett (2005) 15(10):2685-2688.
62. Rishton GM, Retz DM, Tempest PA, Novotny J, Kahn S, Treanor JJS, Lile JD, Citron M: Fenchylamine sulfonamide inhibitors of amyloid β peptide production by the γ-secretase proteolytic pathway: Potential small molecule therapeutic agents for the treatment of Alzheimer's disease. J Med Chem (2000) 43(12):2297-2299.
63. Lewis SJ, Smith AL, Neduvelil JG, Stevenson GI, Lindon MJ, Jones AB, Shearman MS, Beher D, Clarke E, Best JD, Peachy JE et al: A novel series of γ-secretase inhibitors based on a benzobicyclo[4.2.1]nonane core. Bioorg Med Chem Lett (2005) 15(2):373-378.
64. Pietrancosta N, Quelever G, Laras Y, Garino C, Burlet S, Kraus JL: Design of γ-secretase inhibitors by introduction of a mandelyl moiety in DAPT analogues. Aust J Chem (2005) 58(8):585-594.
65. WYETH CORP/ARQULE INC (Kreft AF, Cole DC, Woller KR, Stock JR, Kutterer KM, Kubrak DM, Mann CW, Moore WJ, Casebier DS): Substituted phenylsulfonamide inhibitors of β amyloid production. WO-2003103660 (2003).
66. SHERING CORP (Asberom T, Clader JW, Josien HB, Pissarnitski DA, Zhao Z, McBriar MD): Novel γ-secretase inhibitors. WO-2005097768 (2005).
67. ATHENA NEUROSCIENCES INC/ELI LILLY CO (Wu J, Tung JS, Thorsett ED, Pleiss MA, Nissen JS, Neitz J, Latimer LH, Varghese J, Freedman S, Britton TC, Audia JE et al): Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds. WO-09828268 (1998).
68. DU PONT PHARMACEUTICALS CO (Olson RE, Liu H, Thompson LA): Hydroxyalkanoyl aminolactams and related structures as inhibitors of Aβ protein production. WO-00119797 (2001).
69. MERCK SHARP & DOHME LTD (Castro PJ, Churcher I, Guiblin AR, Harrison T, Kerrad S, Madin A, Nadin JA, Owens AP, Sparey TJ, Teall MR, Williams S): Benzodiazepine derivatives as APP modulators. WO-00190084 (2001).
70. DU PONT PHARMACEUTICALS CO (Olson RE, Maduskuie TP, Thomas LA): Succinoylamino lactams as inhibitors of Aβ-peptide production. WO-00007995 (2000).
71. ELAN PHARMACEUTICAL INC/PHARMACIA & UPJOHN CO (Hom R, Tucker J, John V, Shah N): 2-Amino- and 2-thio-substituted 1,3-diaminopropanes. WO-2005095326 (2005).
72. ELAN PHARMACEUTICALS INC (John V, Maillard M, Fang L, Tucker J, Brogley L, Aquino J, Bowers S, Probst G, Tung J): Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors. WO-2005087714 (2005).
73. MERCK & CO INC (Nantermet PG, Rajapakse HA, Selnick HG, Stauffer SR, Young MB): Benzylether and benzylamino β-secretase inhibitors for the treatment of Alzheimer's disease. WO-2005051914 (2005).
74. MERCK & CO INC (Nantermet PG, Rajapakse HA, Selnick HG): Benzyl ethers and benzylamines as β-secretase inhibitors for the treatment of Alzheimer's disease. WO-2005032471 (2005).
75. MERCK & CO INC (Barrow JC, Mcgaughey GB, Nantermet PG, Rajapakse HA, Selnick HG, Stauffer SR, Cobum CA): 1,3,5-Substituted phenyl derivative compounds useful as β-secretase inhibitors for the treatment of Alzheimer's disease. WO-2005103020 (2005).
76. MERCK & CO INC (Barrow JC, McGaughey GB, Nantermet PG, Rajapakse HA, Selnick HG, Stauffer SR, Vacca JP, Stachel SJ, Cobum CA, Stanton MG): 2,4,6-Substituted pyridyl derivative compounds useful as β-secretase inhibitors for the treatment of Alzheimer's disease. WO-2005103043 (2005).
77. MERCK & CO INC (Barrow JC, Cobum CA, Nantermet PG, Selnick HG, Stachel SJ, Stanton MG, Stauffer SR, Zhuang L, Davis JR): Phenylamide and pyridylamide β-secretase inhibitors for the treatment of Alzheimer's disease. WO-2005065195 (2005).